What it's for (Indications)
- Brimonidine tartrate + timolol maleate ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- This combination medication is particularly suitable for patients who require additional IOP lowering beyond what is achieved with a single ophthalmic anti-glaucoma medication, or for those who have not responded adequately to monotherapy.
- The fixed-combination formulation leverages the complementary mechanisms of action of its two active ingredients, providing an additive effect in lowering IOP, which is a primary risk factor for the progression of glaucomatous optic neuropathy.
- Its use helps in preventing further damage to the optic nerve and preserving visual field, representing a crucial therapeutic option in the long-term management of these chronic eye conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for brimonidine tartrate + timolol maleate ophthalmic solution is one drop in the affected eye(s) twice daily, approximately 12 hours apart. It is crucial for patients to adhere strictly to the prescribed dosing regimen to maintain consistent intraocular pressure control throughout the day and night. If more than one topical ophthalmic medication is being used, the patient should wait at least five minutes between administrations of the different medications to prevent washout and ensure proper absorption. Patients should be instructed on proper instillation techniques to minimize systemic absorption and potential side effects, including gentle pressure on the lacrimal sac at the medial canthus for one to two minutes after instillation (punctal occlusion). Exceeding the recommended dose may increase the risk of systemic adverse reactions without conferring additional therapeutic benefit. |
Safety & Warnings
Common Side Effects
- Common ocular side effects associated with brimonidine tartrate + timolol maleate ophthalmic solution include ocular irritation (such as burning, stinging, or discomfort), conjunctival hyperemia (redness), blurred vision, foreign body sensation, ocular pruritus (itching), and ocular allergic reactions.
- Systemic side effects may also occur due to absorption of the active ingredients.
- These can include dry mouth, fatigue, somnolence (drowsiness), headache, and taste perversion, primarily attributed to brimonidine.
- Timolol's systemic absorption can lead to more serious adverse events such as bradycardia (slow heart rate), hypotension (low blood pressure), dizziness, depression, and respiratory symptoms including dyspnea (shortness of breath) or exacerbation of asthma/COPD.
- Less frequently, but potentially severe, side effects may encompass syncope, heart failure, and allergic reactions including rash and angioedema.
- Patients should report any persistent or worsening side effects to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Serious Warnings: Due to the systemic absorption of timolol maleate, a beta-adrenergic blocking agent, this ophthalmic solution can exert significant cardiovascular and pulmonary effects. Patients with pre-existing conditions such as bronchial asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock are at a substantially increased risk of experiencing serious adverse reactions, including exacerbation of respiratory distress, severe bradycardia, heart block, and cardiac failure. Careful assessment of the patient's medical history, particularly cardiac and pulmonary status, is paramount prior to and during treatment with this medication. Physicians should be vigilant for signs of systemic beta-blockade, especially in patients who are simultaneously receiving oral beta-blockers or other cardioactive drugs. Furthermore, brimonidine tartrate can cause clinically significant central nervous system (CNS) depression (e.g., somnolence, fatigue) and hypotension. This effect is particularly pronounced and dangerous in infants and young children (under 2 years of age), for whom this medication is contraindicated due to the high risk of severe systemic events, including apnea, bradycardia, and hypothermia. Extreme caution is advised when prescribing to patients with cardiovascular disease, depression, cerebral or coronary insufficiency, or those concomitantly using other CNS depressants.
- Due to the systemic absorption of timolol maleate, this ophthalmic solution can cause cardiovascular and respiratory adverse effects similar to those seen with orally administered beta-adrenergic blocking agents.
- Patients with a history of bronchial asthma, chronic obstructive pulmonary disease (COPD), or pre-existing cardiovascular conditions such as bradycardia, heart block, or heart failure, are at particular risk.
- Brimonidine tartrate can cause central nervous system (CNS) depression, including somnolence and fatigue, and may also cause hypotension, particularly in pediatric patients where it is contraindicated.
- Caution is advised in patients with cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
- The medication should be used with caution in patients with diabetes mellitus, as beta-blockers can mask the signs and symptoms of acute hypoglycemia.
- Patients undergoing surgery should be carefully managed, as beta-blockade may impair the heart's ability to respond to adrenergic stimuli.
- Concomitant use with other CNS depressants, antihypertensives, or cardiac glycosides requires careful monitoring due to potential additive effects.
How it Works (Mechanism of Action)
Brimonidine tartrate + timolol maleate ophthalmic solution combines two distinct agents that work synergistically to reduce elevated intraocular pressure (IOP). Brimonidine tartrate is an alpha-2 adrenergic agonist that acts by both reducing the production of aqueous humor and increasing uveoscleral outflow. Its dual mechanism contributes to a significant lowering of IOP. Timolol maleate is a non-selective beta-adrenergic receptor blocker. Its primary mechanism of action in lowering IOP is by reducing the rate of aqueous humor production in the ciliary body. The combined effect of these two medications, targeting different pathways involved in aqueous humor dynamics, provides an enhanced and more sustained IOP reduction compared to either agent used alone. This multi-pronged approach ensures a potent hypotensive effect on the eye, which is critical for managing glaucoma and ocular hypertension.
Commercial Brands (Alternatives)
No other brands found for this formula.